VIVAZEN Clinical Study Demonstrates Safe Kratom Extract Profile Over 28 Days

Why it matters

As FDA-funded clinical trials on kratom expand, industry-sponsored safety data showing tolerability over 28 days contributes to the evolving evidence base on kratom's pharmacological profile in human subjects.

The big picture

Kratom research has historically relied on retrospective case reports and animal studies. This represents one of the first prospective clinical evaluations of a proprietary kratom extract in healthy adults. The study adds to growing interest from FDA and researchers in understanding kratom's safety parameters, though questions remain about generalizability to whole-leaf products and long-term use.

Key findings

• 28-day study of VIVAZEN's proprietary kratom extract showed no severe adverse events in adult participants; No observed evidence of dependence or withdrawal during the trial period; Kratom extracts were well-tolerated for consecutive daily use over four weeks; Study presented at University of Florida Fifth Scientific Kratom Symposium, indicating peer engagement with findings

What they say

Policy should be informed by scientific evidence, not fear-based assumptions. Consumers rely on and deserve transparency and robust safety standards to make informed decisions about their wellness - Dr. Paula Brown, principal investigator.

Bottom line

Industry-sponsored clinical data suggests kratom extracts may be well-tolerated at standard doses, but further independent research and quality control improvements are needed before definitive safety conclusions can be drawn.